Biological Role of Leptin in Management of Obesity
Nowadays obesity is a major health problem all over the worlds especially in developed and developing countries. A person with a BMI equal to or more than 25 is considered overweight. Excess body weight is a result of an imbalance between energy intake and energy expenditure. Obesity is responsible for a number of health complications like diabetic and cardiovascular. Drugs available in market posses a number of adverse effects. Leptin is adipose derived cytokine which is essential for regulation of body weight and energy balance. Leptin regulate lipid profile and glucose metabolism, neuroendocrine functions. Leptin exerts immediate effects by acting on the brain to regulate appetite. Leptin is the first identified adipose-tissue-derived cytokine, which exerts profound functions in the regulation of food intake, energy expenditure, glucose metabolism, reproduction and immune response.
2.Haslam DW, James WPT. Obesity. Lancet 2005; 366: 1197–209.
3.Mauro M, Taylor V, Wharton S, Sharma AM. Barriers to obesity treatment. European Journal of Internal Medicine 2008; 19:173–180
4.Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM.1994. Positional cloning of the mouse obese gene and its human homologue. Nature. 372:425–432.
5.Boguszewski CL, Paz-Filho G, Velloso LA. Neuroendocrine body weight regulation: integration between fat tissue, gastrointestinal tract, and the brain. Endokrynol Pol 2010; 61:194–206.
6.Bell-Anderson KS, Bryson JM. Leptin as a potential treatment for obesity: progress to date. Treat Endocrinol. 2004; 3(1):11-8.
7.Mantzoros CS, Magkos F, Brinkoetter M, Sienkiewicz E, Dardeno TA, Kim SY, et al. Leptin in human physiology and pathophysiology. Am J Physiol Endocrinol Metab 2011; 301: E567–84.
8.Paz-Filho G, Wong ML, Licinio J. Ten years of leptin replacement therapy. Obes Rev 2011; 12:e315–23.
9.Boguszewski CL, Paz-Filho G, Velloso LA. Neuroendocrine body weight regulation: integration between fat tissue, gastrointestinal tract, and the brain. Endokrynol Pol 2010; 61: 194–206.
10.Das UN. Is obesity an inflammatory condition? Nutrition 2001; 17: 953–966.
11.Ahima RS, Flier JS. Leptin. Annu. Rev. Physiol.2000; 62: 413–437.
12.Schwartz MW, Woods SC, Porte D, Seeley RJ. Baskin DG, Central nervous system control of food intake. Nature. 2000; 404:661–671.
13.Bell-Anderson KS, Bryson JM. Leptin as a potential treatment for obesity: progress to date, Treat Endocrinol. 2004;3(1):11-8.
14.Considine RV, Sinha MK, Heiman ML, Kriauciunas A, Stephens TW, Nyce MR, et al. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med 1996; 334 (5):292–5.
15.Licinio J, Mantzoros C, Negrao AB, Cizza G, Wong ML, Bongiorno PB, et al. Human leptin levels are pulsatile and inversely related to pituitary-adrenal function. Nat Med 1997;3(5):575–9.
16.Sinha MK, Ohannesian JP, Heiman ML, Kriauciunas A, Stephens TW, Magosin S, et al. Nocturnal rise of leptin in lean, obese, and non-insulin-dependent diabetes mellitus subjects. J Clin Invest. 1996; 97 (5):1344–7.
17.Meek TH, Morton GJ. The role of leptin in diabetes: metabolic effects. Diabetologia 2016; First online: 1-5
18.Licinio J, Caglayan S, Ozata M, Yildiz BO, de Miranda PB, O'Kirwan F, et al. Phenotypic effects of leptin replacement on morbid obesity, diabetes mellitus, hypogonadism, and behavior in leptin-deficient adults. Proc Natl Acad Sci USA 2004; 101:4531–6.
19.Farooqi IS, Matarese G, Lord GM, Keogh JM, Lawrence E, Agwu C, et al. Beneficial effects of leptin on obesity, T cell hyporesponsiveness, and neuroendocrine/metabolic dysfunction of human congenital leptin deficiency. J Clin Invest. 2002; 110:1093–103.
20.Gibson WT, Farooqi IS, Moreau M, De Paoli AM, Lawrence E, O'Rahilly S, et al. Congenital leptin deficiency due to homozygosity for the Delta133G mutation: report of another case and evaluation of response to four years of leptin therapy. J Clin Endocrinol Metab. 2004; 89:4821–6.
21.Lee YH, Magkos F, Mantzoros CS, Kang ES. Effects of leptin and adiponectin on pancreatic beta-cell function. Metabolism 2011; 60:1664–72.
22.Andreev VP, Paz-Filho G, Wong ML, Licinio J. Deconvolution of insulin secretion, insulin hepatic extraction post-hepatic delivery rates and sensitivity during 24-hour standardized meals: time course of glucose homeostasis in leptin replacement treatment. Horm Metab Res 2009; 41:142–51.
23. Paz-Filho G, Esposito K, Hurwitz B, Sharma A, Dong C, Andreev V, et al. Changes in insulin sensitivity during leptin replacement therapy in leptin-deficient patients. Am J Physiol Endocrinol Metab 2008; 295: E1401–8.
24. Chan JL, Bullen J, Stoyneva V, Depaoli AM, Addy C, Mantzoros CS. Recombinant methionyl human leptin administration to achieve high physiologic or pharmacologic leptin levels does not alter circulating inflammatory marker levels in humans with leptin sufficiency or excess. J Clin Endocrinol Metab 2005;90(3):1618–24.
25. Chan JL, Moschos SJ, Bullen J, Heist K, Li X, Kim YB, et al. Recombinant methionyl human leptin administration activates signal transducer and activator of transcription 3 signaling in peripheral blood mononuclear cells in vivo and regulates soluble tumor necrosis factor-alpha receptor levels in humans with relative leptin deficiency. J Clin Endocrinol Metab 2005; 90(3):1625–31.
26.Robertson SA, Leinninger GM, Myers MG Jr. Molecular and neural mediators of leptin action. Physiol Behav. 2008; 94(5):637–42.
27.Haynes WG, Morgan DA, Walsh SA, Mark AL, Sivitz WI. Receptor-mediated regional sympathetic nerve activation by leptin. J Clin Invest 1997; 100(2):270–8.
28.Collins S, Kuhn CM, Petro AE, Swick AG, Chrunyk BA, Surwit RS. Role of leptin in fat regulation. Nature. 1996; 380(6576):677.
29.Scarpace PJ, Matheny M, Pollock BH, Tumer N. Leptin increases uncoupling protein expression and energy expenditure. Am J Physiol. 1997;273(1 Pt 1):E226–30.
30.Chan JL, Mietus JE, Raciti PM, Goldberger AL, Mantzoros CS. Short-term fasting-induced autonomic activation and changes in catecholamine levels are not mediated by changes in leptin levels in healthy humans. Clin Endocrinol 2007; 66(1):49–57.
31.Boden G, Chen X, Mozzoli M, Ryan I. Effect of fasting on serum leptin in normal human subjects. J Clin Endocrinol Metab 1996; 81(9):3419–23.
32.Chan JL, Heist K, DePaoli AM, Veldhuis JD, Mantzoros CS. The role of falling leptin levels in the neuroendocrine and metabolic adaptation to short-term starvation in healthy men. J Clin Invest 2003; 111(9):1409–21.
33.Chan JL, Matarese G, Shetty GK, Raciti P, Kelesidis I, Aufiero D, et al. Differential regulation of metabolic, neuroendocrine, and immune function by leptin in humans. Proc Natl Acad Sci U S A 2006; 103(22):8481–6.
34.Ahima RS, Prabakaran D, Mantzoros C, Qu D, Lowell B, Maratos-Flier E, et al. Role of leptin in the neuroendocrine response to fasting. Nature 1996;382(6588):250–2.
35.Harris RB, Zhou J, Redmann SM Jr, Smagin GN, Smith SR, Rodgers E, et al. A leptin dose-response study in obese (ob/ob) and lean (+/?) mice. Endocrinology 1998; 139(1):8–19.
36.Farooqi IS, Matarese G, Lord GM, Keogh JM, Lawrence E, Agwu C, et al. Beneficial effects of leptin on obesity, T cell hypo responsiveness, and neuroendocrine/metabolic dysfunction of human congenital leptin deficiency. J Clin Invest 2002; 110(8):1093–103.
37.Gavrilova O, Marcus-Samuels B, Graham D, Kim JK, Shulman GI, Castle AL, et al. Surgical implantation of adipose tissue reverses diabetes in lipoatrophic mice. J Clin Invest 2000; 105(3):271–8.
38.Shimomura I, Hammer RE, Ikemoto S, Brown MS, Goldstein JL. Leptin reverses insulin resistance and diabetes mellitus in mice with congenital lipodystrophy. Nature. 1999; 401(6748):73–6.
39.Kim JK, Gavrilova O, Chen Y, Reitman ML, Shulman GI. Mechanism of insulin resistance in A-ZIP/,F-1 fatless mice. J Biol Chem 2000; 275(12):8456–60.
40.Brennan AM, Lee JH, Tsiodras S, Chan JL, Doweiko J, Chimienti SN, et al. r-metHuLeptin improves highly active antiretroviral therapy-induced lipoatrophy and the metabolic syndrome, but not through altering circulating IGF and IGF-binding protein levels: observational and interventional studies in humans. Eur J Endocrinol 2009; 160(2):173–6.
41.Ebihara K, Masuzaki H, Nakao K. Long-term leptin-replacement therapy for lipoatrophic diabetes. N Engl J Med. 2004; 351(6):615–6.
42.Javor ED, Cochran EK, Musso C, Young JR, Depaoli AM, Gorden P. Long-term efficacy of leptin replacement in patients with generalized lipodystrophy. Diabetes 2005; 54(7):1994–2002.
43.Javor ED, Ghany MG, Cochran EK, Oral EA, DePaoli AM, Premkumar A, et al. Leptin reverses nonalcoholic steatohepatitis in patients with severe lipodystrophy. Hepatology 2005; 41(4):753–60.
44.Lee JH, Chan JL, Sourlas E, Raptopoulos V, Mantzoros CS. Recombinant methionyl human leptin therapy in replacement doses improves insulin resistance and metabolic profile in patients with lipoatrophy and metabolic syndrome induced by the highly active antiretroviral therapy. J Clin Endocrinol Metab 2006;91(7):2605–11.
45.Mulligan K, Khatami H, Schwarz JM, Sakkas GK, DePaoli AM, Tai VW, et al. The effects of recombinant human leptin on visceral fat, dyslipidemia, and insulin resistance in patients with human immunodeficiency virus-associated lipoatrophy and hypoleptinemia. J Clin Endocrinol Metab 2009; 94(4):1137–44.
46.Oral EA, Simha V, Ruiz E, Andewelt A, Premkumar A, Snell P, et al. Leptin-replacement therapy for lipodystrophy. N Engl J Med. 2002; 346(8):570–8.
47.Petersen KF, Oral EA, Dufour S, Befroy D, Ariyan C, Yu C, et al. Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy. J Clin Invest 2002; 109(10):1345–50.